Oncology & Cancer

Long-term cardiomyopathy risk varies by chemo agent

(HealthDay)—Long-term cardiomyopathy risk varies by chemotherapy agent for childhood cancer survivors, with a decreased risk for daunorubicin versus doxorubicin, according to a study recently published in JAMA Oncology.

Oncology & Cancer

New drug brings unexpected hope in targeting cancer cells

An unexpected finding in pre-clinical platelet studies by Baker Institute researchers could provide a novel approach to targeting and destroying difficult-to-treat cancer cells, providing new therapeutic options for a range ...

Oncology & Cancer

Surgery often sufficient to avoid recurrence in colon cancer

A new study from Uppsala University shows that many patients with colon cancer do not need any chemotherapy and that among patients who benefit from chemotherapy it does not have to be as intense for everyone.

Oncology & Cancer

Novel diabetes drugs sensitize cancer cells to chemotherapy agents

Scientists at Dana-Farber Cancer Institute have shown that experimental diabetes drugs can make cancer cells more vulnerable to traditional chemotherapy agents, and they say such combinations should be explored to potentially ...

page 1 from 10